Equivalence-by-design: Targeting in vivo drug delivery profile

Pharmaceutical Research

Volumn 25, Issue 12, 2008, Pages 2723-2730

  Chen, Mei Ling ^a   Lee, Vincent H L ^b  

^a CENTER FOR DRUG EVALUATION AND RESEARCH   (United States)

^b and Hong Kong Branch of CAS Center for Excellence in Animal Evolution and Genetics   (Hong Kong)

Author keywords

Bioequivalence; In vivo drug delivery profile; Pharmaceutical equivalence; Quality by design; Therapeutic equivalence

Indexed keywords

ADALAT CC; EXCIPIENT; NIFEDIPINE; POLYSORBATE 80; SORBITOL; UNCLASSIFIED DRUG;

BIOAVAILABILITY; BIOEQUIVALENCE; CONFERENCE PAPER; CONTROLLED DRUG RELEASE; DRUG DELIVERY SYSTEM; DRUG DESIGN; DRUG DOSAGE FORM; DRUG FORMULATION; FOOD AND DRUG ADMINISTRATION; IN VIVO STUDY; PRIORITY JOURNAL; UNITED STATES;

CHEMISTRY, PHARMACEUTICAL; DOSAGE FORMS; DRUG DELIVERY SYSTEMS; HUMANS; RESEARCH DESIGN; THERAPEUTIC EQUIVALENCY;

EID: 57149126212     PISSN: 07248741     EISSN: 1573904X     Source Type: Journal    
DOI: 10.1007/s11095-008-9743-8     Document Type: Conference Paper

References (95)

1. Electronic Orange Book: Approved Drug Products with Therapeutic Equivalence Evaluations. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Current through February 2008. http://www.fda.gov/cder/ob/default.htm
2. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.25(a), Office of Federal Register, National Archives and Records Administration (2007).
3. Drug Bioequivalence Study Panel. Drug bioequivalence. Office of Technology Assessment, Superintendent of Documents, U.S. Government Printing Office, Washington DC 20402 (1974).
4. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320, Office of Federal Register, National Archives and Records Administration (2006).
5. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance Documents, accessed on March 3, 2008. http://www.fda.gov/cder/guidance/index.htm
6. Pharmaceutical Manufacturers Association, A presentation to the U.S. Food and Drug Administration Hearing on Bioequivalence of Solid Oral Dosage Forms, September 29-October 1, 1986.
7. U.S. Department of Health and Human Services, Food and Drug Administration, Establishment of the Therapeutic Inequivalence Action Coordinating Committee; Availability of committee reports, 53 Federal Register 35562, September 14, 1988.
8. M.-L. Chen R. Patnaik W.W. Hauck D.J. Schuirmann T. Hyslop R.L. Williams FDA Population/Individual Bioequivalence Working Group 2000 An individual bioequivalence criterion: Regulatory considerations Stat. Med. 19 2821 2842
9. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Office of Generic Drugs. Critical Path Opportunities for Generic Drugs. May 1, 2007. http://www.fda.gov/oc/initiatives/criticalpath/ reports/generic.html
10. S. Sabatini R.M. Ferguson J.H. Helderman 1999 Drug substitution in transplantation: A National Kidney Foundation white paper Am. J. Kidney Dis. 33 389 397
11. F.M.C. Besag 2000 Is generic prescribing acceptable in epilepsy? Drug Safety. 23 173 182
12. J.A. Reiffel 2001 Issues in the use of generic antiarrhythmic drugs Curr. Opin. Cardiol. 16 23 29
13. L.S. Welage D.M. Kirking F.J. Ascione C.A. Gaither 2001 Understanding the scientific issues embedded in the generic drug approval process J. Am. Pharm. Assoc. 41 856 867
14. Y.W.F. Lam L. Ereshefsky G.B. Toney C. Gonzales 2001 Branded versus generic clozapine: bioavailability comparison and interchangeability issues J. Clin. Psychiatry. 62 suppl 5 18 22
15. L. Wartofsky 2002 Levothyroxine: Therapeutic use and regulatory issues related to bioequivalence Exp. Opin. Pharmacother. 3 727 732
16. G. Borgherini 2003 The bioequivalence and therapeutic efficacy of generic versus brand-name psychoactive drugs Clin. Ther. 25 1578 1592
17. P. Meredith 2003 Bioequivalence and other unresolved issues in generic drug substitution Clin. Ther. 25 2875 2890
18. R.A. Bongiorno E.A. Nutescu 2004 Generic warfarin: Implications for clinical practice and perceptions of anticoagulation providers Semin. Thromb. Hemost. 30 619 626
19. V. Blakesley W. Awni C. Locke T. Ludden G.R. Granneman L.E. Braverman 2004 Are bioequivalence studies of levothyroxine sodium formulations in euthyroid volunteers reliable? Thyroid. 14 191 200
20. T.E. Welty 2007 Pharmacy and generic substitution of antiepileptic drugs: Missing in action? Ann. Pharmacother. 41 1065 1068
21. M. Healy. FDA standards for generics are questioned. Los Angeles Times, March 17, 2008.
22. U.S. Department of Health and Human Services, Food and Drug Administration, Innovation/Stagnation: Challenge and Opportunity on the Critical Path to New Medical Products. March 2004. http://www.fda.gov/oc/initiatives/ criticalpath/whitepaper.html
23. D.J. Burgess A.S. Hussain T.S. Ingallinera M.-L. Chen 2002 Assuring quality and performance of sustained and controlled release parenterals: Workshop report Pharm. Res. 19 1761 1768
24. D.J. Burgess D.J.A. Crommelin A.S. Hussain M.-L. Chen 2004 Assuring quality and performance of sustained and controlled release parenterals: EUFEPS workshop report Eur. J. Pharm. Sci. 21 769 790
25. K. Kumi. Complex drug substances - liposome drug products: Bioavailability and bioequivalence (biopharmaceutics issues). U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Advisory Committee for Pharmaceutical Science Meeting, May 3-4, 2005. http://www.fda.gov/ohrms/ dockets/ac/01/slides/3763s2.htm
26. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.1, Office of Federal Register, National Archives and Records Administration (2006).
27. J.E. Henney 2000 Nationwide recall of SangCya oral solution JAMA. 284 1234
28. M.-L. Chen 2008 Lipid excipients and delivery systems for pharmaceutical development Adv. Drug Deliv. Rev. 60 768 777
29. R. Lionberger, Topical bioequivalence update. U.S. Food and Drug Administration, Center for Drug Evaluation and Research. Advisory Committee for Pharmaceutical Science Meeting, May 3-4, 2005. http://www.fda.gov/ohrms/dockets/ 9ac/05/briefing/2005-4137b1_Index.htm
30. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Bioavailability and Bioequivalence Studies for Orally Administered Drug Products - General Considerations. Division of Drug Information, HFD-240, Rockville, Maryland 20857, March 2003. http://www.fda.gov/cder/guidance/5356fnl.doc
31. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.24(a), Office of Federal Register, National Archives and Records Administration (2006).
32. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.24(b), Office of Federal Register, National Archives and Records Administration (2006).
33. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Waiver of In Vivo Bioavailability and Bioequivalence Studies for Immediate Release Solid Oral Dosage Forms Based on a Biopharmaceutics Classification System. Office of Training and Communication, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, Maryland 20857, August 2000. http://www.fda.gov/cder/guidance/3618fnl.htm
34. U.S. Food and Drug Administration, Title 21 Code of Federal Regulations (CFR) Part 320.22, Office of Federal Register, National Archives and Records Administration (2006).
35. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Corticosteroids, Dermatologic (topical) In Vivo. Office of Training and Communication, Division of Communications Management, Drug Information Branch, HFD-210, Rockville, Maryland 20857, June 1995. http://www.fda.gov/cder/guidance/ old098fn.pdf
36. P.D.R. Thomson. Physicians' Desk Reference (PDR). 57Author, Montvale, NJ, 2003.
37. P.D.R. Thomson. Physicians' Desk Reference (PDR). 59Author, Montvale, NJ, 2005.
38. T. Bussemer I. Otto R. Bodmeier 2001 Pulsatile drug-delivery systems Crit. Rev. Ther. Drug Carrier Syst. 18 433 58
39. D.J. Brayden 2003 Controlled release technologies for drug delivery Drug Discovery Today. 8 976 978
40. A. Farinha A. Bica J.P. Pais M.C. Toscano P. Tavares 1999 Bioequivalence evaluation of two omeprazole enteric-coated formulations in humans Eur. J. Pharm. Sci. 7 311 315
41. Z. Elkoshi D. Behr A. Mirimsky I. Tsvetkov A. Danon 2002 Multiple-dose studies can be a more sensitive assessment for bioequivalence than single-dose studies-The case with omeprazole Clin. Drug Invest. 22 585 592
42. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Draft Guidance for Industry: Liposome Drug Products - Chemistry, Manufacturing and Controls; Human Pharmacokinetics and Bioavailability; and Labeling Documentation. Office of Training and Communications, Division of Drug Information, HFD-240, Rockville, MD. http://www.fda.gov/cder/guidance/2191dft.pdf
43. U.S. Department of Health and Human Services, Food and Drug Administration, Center for Devices and Radiological Health (CDRH), Center for Drug Evaluation and Research. Draft Guidance for Industry: Coronary Drug-Eluting Stents - Nonclinical and Clinical Studies. Office of Training and Communications, Division of Communications Management, HFD-210, Rockville, MD. http://www.fda.gov/cdrh/ode/guidance/6255.html
44. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Generic Drugs, Division of Bioequivalence. Interim Guidance: Cholestyramine Powder-In Vitro Bioequivalence. July 1993. http://www.fda.gov/ cder/guidance/cholesty.pdf
45. M.-L. Chen A.J. Jackson 1991 The role of metabolites in bioequivalency assessment. I. Linear pharmacokinetics without first-pass effect Pharm. Res. 8 25 32
46. M.-L. Chen A.J. Jackson 1995 The role of metabolites in bioequivalency assessment. I. Drugs with linear pharmacokinetics without first-pass effect Pharm. Res. 12 700 708
47. F.H. Roerdink J. Regts T. Handel S.M. Sullivan J.D. Baldeschwieler G.L. Scherphof 1989 Effect of cholesterol on the uptake and intracellular degradation of liposomes by liver and spleen; a combined biochemical and γ-ray perturbed angular correlation study Biochim. Biophys. Acta. 980 234 240
48. M.-L. Chen. Novel approaches to establishing equivalence of advanced dosage forms. American Association for Pharmaceutical Scientists (AAPS) Annual Meeting and Exposition, San Diego, November 11-15, 2007.
49. S. Arora J. Ali A. Ahuja R.K. Khar S. Baboota 2005 Floating drug delivery systems: A review AAPS Pharm. Sci. Tech. 6 03 E372 E390
50. P.D. Dobson D.B. Kell 2008 Carrier-mediated cellular uptake of pharmaceutical drugs: an exception or the rule? Nat. Rev.-Drug Discov. 7 205 220
51. T.M. Sissung E.R. Gardner R. Gao W.D. Figg 2008 Pharmacogenetics of membrane transporters: A review of current approaches Methods Mol. Biol. 448 41 62
52. M. Takano R. Yumoto T. Murakami 2006 Expression and function of efflux drug transporters in the intestine Pharmacol. Ther. 109 137 161
53. Y. Su P.J. Sinko 2006 Drug delivery across the blood-brain barrier: Why is it difficult? How to measure and improve it? Expert Opin. Drug Deliv. 3 419 435
54. U. Hoffmann H.K. Kroemer 2004 The ABCC transporters MDR1 and MRP2: multiple functions in disposition of xenobiotics and drug resistance Drug Metab. Rev. 36 669 701
55. L.Z. Benet C.L. Cummins C.Y. Wu 2004 Unmasking the dynamic interplay between efflux transporters and metabolic enzymes Int. J. Pharm. 11 3 9
56. B. Steffansen C.U. Nielsen B. Brodin A.H. Eriksson R. Andersen S. Frokjaer 2004 Intestinal solute carriers: An overview of trends and strategies for improving oral drug absorption Eur. J. Pharm. Sci. 21 3 16
57. N. Mizuno T. Niwa Y. Yotsumoto Y. Sugiyama 2003 Impact of drug transporter studies on drug discovery and development Pharmacol. Rev. 55 425 461
58. R.B. Kim 2002 Drugs as P-glycoprotein substrates, inhibitors, and inducers Drug Metab. Rev. 34 47 54
59. K.M. Koch A.F. Parr J.J. Tomlinson E.P. Sandefer G.A. Digenis K.H. Donn J.R. Powell 1993 Effect of sodium acid pyrophosphate on ranitidine bioavailability and gastrointestinal transit time Pharm. Res. 10 1027 1030
60. D.A. Adkin S.S. Davis R.A. Sparrow P.D. Huckle A.J. Philips I.R. Wilding 1995 The effects of pharmaceutical excipients on small intestinal transit Br. J. Clin. Pharmac. 39 381 387
61. D.A. Adkin S.S. Davis R.A. Sparrow P.D. Huckle I.R. Wilding 1995 The effect of mannitol on the oral bioavailability of cimetidine J. Pharm. Sci. 84 1405 1409
62. M.M. Nerurkar P.S. Burton R.T. Borchardt 1996 The use of surfactants to enhance the permeability of peptides through Caco-2 cells by inhibition of an apically polarized efflux system Pharm. Res. 13 528 534
63. L. Yu A. Bridgers J. Polli A. Vickers S. Long A. Roy R. Winnike M. Coffin 1999 Vitamin E-TPGS increases absorption flux of an HIV protease inhibitor by enhancing its solubility and permeability Pharm. Res. 16 1812 1817
64. B. J. Aungst 2000 Intestinal permeation enhancers J. Pharm. Sci. 89 429 442
65. A. Bernkop-Schnurch 2000 Chitosan and its derivatives: potential excipients for peroral peptide delivery systems Int. J. Pharm. 194 1 13
66. B.D. Rege L.X. Yu A.S. Hussain J.E. Polli 2001 Effect of common excipients on Caco-2 transport of low-permeability drugs J. Pharm. Sci. 90 1776 1786
67. A.W. Basit F. Podczeck J.M. Newton W.A. Waddington P.J. Ell L.F. Lacey 2002 Influence of polyethylene glycol 400 on the gastrointestinal absorption of ranitidine Pharm. Res. 19 1368 1374
68. B.D. Rege J.P.Y. Kao J.E. Polli 2002 Effect of nonionic surfactants on membrane transporters in Caco-2 cell monolayers Eur. J. Pharm. Sci. 16 237 246
69. E.D. Hugger B.L. Novak P.S. Burton K.L. Audus R.T. Borchardt 2002 A comparison of commonly used polyethoxylated pharmaceutical excipients on their ability to inhibit p-glycoprotein activity in vitro J. Pharm. Sci. 91 1991 2002
70. J.D.R. Schulze W.A. Waddington P.J. Ell G.E. Parsons M.D. Coffin A.W. Basit 2003 Concentration-dependent effects of polyethylene glycol 400 on gastrointestinal transit and drug absorption Pharm. Res. 20 1984 1988
71. T. Nozawa H. Toyobuku D. Kobayashi K. Kuruma A. Tsuji I. Tamai 2003 Enhanced intestinal absorption of drugs by activation of peptide transporter PEPT1 using proton-releasing polymer J. Pharm. Sci. 92 2208 2216
72. Y. Tayrouz R. Ding J. Burhenne K.D. Riedel J. Weiss T. Hoppe-Tichy W.E. Haefeli G. Mikus 2003 Pharmacokinetic and pharmaceutic interaction between digoxin and Cremophor RH40 Clin. Pharmacol. Ther. 73 397 405
73. K. Bogman Y. Zysset L. Degen G. Hopfgartner H. Gutmann J. Alsenz J. Drewe 2005 P-glycoprotein and surfactants: Effect on intestinal talinolol absorption Clin. Pharmacol. Ther. 77 24 32
74. P.P. Constantinides K.M. Wasan 2007 Lipid formulation strategies for enhancing intestinal transport and absorption of P-glycoprotein (P-gp) substrate drugs: In vitro/in vivo case studies J. Pharm. Sci. 96 235 248
75. M.-L. Chen A.B. Straughn N. Sadrieh M. Meyer P.J. Faustino A.B. Ciavarella B. Meibohm C.R. Yates A.S. Hussain 2007 A modern view of excipient effects on bioequivalence: Case study of sorbitol Pharm. Res. 24 73 80
76. J.M. Odeberg A. Lignell A. Pettersson P. Hoglund 2003 Oral bioavailability of the antioxidant astaxanthin in humans is enhanced by incorporation of lipid based formulations Eur. J. Pharm. Sci. 19 299 304
77. J. Senior J.C.W. Crawley G. Gregoriadis 1985 Tissue distribution of liposomes exhibiting long half-lives in the circulation after intravenous injection Biochim. Biophys. Acta. 839 1 8
78. S.M. Morghimi H.M. Patel 1998 Serum-mediated recognition of liposomes by phagocytic cells of the reticuloendothelial system-The concept of tissue specificity Adv. Drug Deliv. Rev. 32 45 60
79. R. Meyer. Clinical relevance of alcohol-induced dose dumping. FDA Advisory Committee for Pharmaceutical Science Meeting, Rockville, Maryland. Oct. 25-26, 2005. http://www.fda.gov/ohrms/dockets/ac/acmenu.htm
80. The International Conference on Harmonization of Technical Requirements for the Registration of Pharmaceuticals for Human Use, ICH E5 Guideline, August 1998; U.S. Department of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research. Guidance for Industry: Ethnic Factors in the Acceptability of Foreign Clinical Data. Federal Register 63:31790-6 (1998).
81. M.-L. Chen 2005 Confounding factors for sex differences in pharmacokinetics and pharmacodynamics: Focus on dosing regimen, dosage form, and formulation Clin. Pharmacol. Ther. 78 322 329
82. K.M. Wasan S.M. Cassidy 1998 Role of plasma lipoproteins in modifying the biological activity of hydrophobic drugs J. Pharm. Sci. 87 411 424
83. K.M. Wasan M. Ramaswamy M. Kwong K.D. Boulanger 2002 Role of plasma lipoproteins in modifying the toxic effects of water-insoluble drugs: Studies with cyclosporine A AAPS PharmSci 4 Article 30
84. D. Fallik. Experts: Patches + Heat = Danger, Philadelphia Inquirer, Mar. 5, 2006. http://www.yourlawyer.com/articles/read/11446
85. M.A. Ashburn L.L. Ogden J. Zhang G. Love S.V. Basta 2003 The pharmacokinetics of transdermal fentanyl delivered with and without controlled heat J. Pain. 4 291 297
86. E. Lundin W. Graf U. Garske S. Nisson E. Maripuu U. Karlbom 2007 Segmental colonic transit studies: comparison of a radiological and a scintigraphic method Colorectal Disease: The Official Journal of the Association of Coloproctology of Great Britain and Ireland. 9 4 344 351
87. B.J. Cook E. Lim D. Cook J. Hughes C.W. Chow M.P. Stanton S.S. Bidarkar B.R. Southwell J.M. Hutson 2005 Radionuclear transit to assess sites of delay in large bowel transit in children with chronic idiopathic constipation J. Pediatr. Surg. 40 478 483
88. A. Perkins M. Frier 2000 Nuclear medicine imaging and drug delivery Nuclear Medicine Communications. 21 415 416
89. S.P. Newman I.R. Wilding 1999 Imaging techniques for assessing drug delivery in man PSTT. 2 5 181 189
90. P.H. Layer H. Goebell J. Keller A. Dignass U. Klotz 1995 Delivery and fate of oral mesalamine microgranules within the human small intestine Gastroenterology. 108 1427 1433
91. G. Meseguer R. Gurny P. Buri 1994 In vivo evaluation of dosage forms: Application of gamma scintigraphy to non-enteral routes of administration J. Drug Target. 2 269 288
92. S.S. Davis J.G. Hardy S.P. Newman I.R. Wilding 1992 Gamma scintigraphy in the evaluation of pharmaceutical dosage forms J. Nucl. Med. 19 11 971 986
93. International Conference on Harmonization of Technical Requirements for Registration of Pharmaceuticals for Human Use. Draft Consensus Guideline on Pharmaceutical Development: Annex to Q8. November 1, 2007. http://www.ich.org/ LOB/media/MEDIA4349.pdf
94. J. Woodcock 2004 The concept of pharmaceutical quality Am. Pharm. Rev. 3 1 3
95. U.S. Food and Drug Administration, Center for Drug Evaluation and Research, Office of Pharmaceutical Science, Advisory Committee for Pharmaceutical Science Meeting, Oct. 5-6, 2006. http://www.fda.gov/ohrms/ dockets/ac/cder06.html#PharmScience